Results 61 to 70 of about 21,338 (215)

Interaction Analysis of Adenovirus L5 Protein With Pancreatic Cancer Cell Surface Receptor to Analyze Its Affinity for Oncolytic Virus Therapy

Frontiers in Oncology, 2022
This study seeks to investigate the interaction profile of the L5 protein of oncolytic adenovirus with the overexpressed surface receptors of pancreatic cancer.
Maryum Nisar, Rehan Zafar Paracha, Alvina Gul, Iqra Arshad, Saima Ejaz, Didar Murad, Shahzeb Khan, Shahzeb Khan, Zartasha Mustansar   +8 more
doaj   +1 more source

Integration of omics data in the diagnosis and therapy of glioblastoma

Brain Pathology, EarlyView.
Integration of omics data in the diagnosis and therapy of glioblastoma. Abstract Since the 2016 update of the WHO Classification of Tumors of the Central Nervous System, omics data have been officially integrated into the diagnostic process for glioblastoma, the most prevalent and aggressive primary malignant brain tumor in adults.
Constantin Möller, Melanie Schoof, Keith L. Ligon, Ulrich Schüller   +3 more
wiley   +1 more source

Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma

Nature Communications
Oncolytic virotherapy holds promise for cancer treatment, but the factors determining its oncolytic activity remain unclear. Neutrophil extracellular traps (NETs) are associated with cancer progression, yet their formation mechanism and role in oncolytic
Weiwei Dai, Ruotong Tian, Liubing Yu, Shasha Bian, Yuling Chen, Bowen Yin, Yuxuan Luan, Siqi Chen, Zhuoyang Fan, Rucheng Yan, Xin Pan, Yingyong Hou, Rong Li, Juxiang Chen, Minfeng Shu   +14 more
doaj   +1 more source

Melanoma update: is a cure now in sight?

Internal Medicine Journal, EarlyView.
Abstract Melanoma, one of the most aggressive skin cancers, poses a significant global health concern due to its high metastatic potential and resistance to conventional treatments. This review explores recent advancements in melanoma treatment, particularly the impact of targeted therapies and immunotherapies which have significantly extended survival
Samrin Liaqat, Muhammad Adnan Khattak
wiley   +1 more source

Comprehensive management of vulvovaginal cancers

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Vulvar and vaginal cancers represent rare malignancies, with an incidence of 2.7 per 100,000 women for vulvar cancer, predominantly affecting women older than 60 years, although rising rates are observed in younger demographics. Approximately 90% of vulvar cancers are squamous cell carcinoma and frequently are associated with human ...
Angélica Nogueira‐Rodrigues, Maaike H. M. Oonk, Domenica Lorusso, Brian Slomovitz, Mario M. Leitão Jr, Glauco Baiocchi   +5 more
wiley   +1 more source

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

Oncolytic Virotherapy, 2017
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery.
Raquel Yokoda, Bolni Nagalo, Brent Vernon, Rahmi Oklu, Hassan Albadawi, Thomas DeLeon, Yumei Zhou, Jan Egan, Dan Duda, Mitesh Borad   +9 more
openaire   +5 more sources

Measles to the Rescue: A Review of Oncolytic Measles Virus [PDF]

Viruses, 2016
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials.
Aref, S, Bailey, K, Fielding, A
openaire   +5 more sources

Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function

Molecular Therapy: Oncolytics, 2019
Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables its ...
Motomu Nakatake, Hajime Kurosaki, Nozomi Kuwano, Kosuke Horita, Mai Ito, Hiromichi Kono, Tomotaka Okamura, Kosei Hasegawa, Yasuhiro Yasutomi, Takafumi Nakamura   +9 more
doaj  

Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions

Cancer Innovation, Volume 4, Issue 4, August 2025.
Glioblastoma (GBM) remains a highly malignant brain tumor with limited treatment efficacy, driving the need for innovative cellular immune theranostic strategies that integrate diagnostic and therapeutic approaches. Recent advances in cellular immunotherapy for GBM include chimeric antigen receptor (CAR)‐T/NK cells, macrophage‐based therapies ...
Ying Gong, Wanying Lin, Xuechun Fang, Ruyi Zhang, Min Luo, Haoran Wu, Shuai Chu, Chuangkun Li, Yiming Peng, Zhiyan Piao, Siping Wu, Junhao Li, ZongZhong He, Haixia Li, Hongxia Wang   +14 more
wiley   +1 more source

Mechanisms of measles virus oncolytic immunotherapy

Cytokine & Growth Factor Reviews, 2020
The study of measles virus (MeV) as a cancer immunotherapeutic was prompted by clinical observations of leukemia and lymphoma regressions in patients following measles virus infection in the 1970s and 1980s. Since then, numerous preclinical studies have confirmed the oncolytic activity of MeV vaccine strains as well as their potential to promote long ...
Gemma Pidelaserra-Martí, Gemma Pidelaserra-Martí, Christine E. Engeland, Christine E. Engeland, Christine E. Engeland   +4 more
openaire   +3 more sources